Table 5 Key canonical pathways associated with inflammation in Il10-/-mice
Canonical Pathways | Number of differentially expressed molecules (P-value) | ||||
|---|---|---|---|---|---|
|  | SPF | C | EF | CIF | EF·CIF |
Ranked according to ratio (differentially expressed genes/total number of genes) | |||||
Antigen Presentation Pathway | 5/39 (< 0.0001) | 5/39 (< 0.0001) | 10/39 (< 0.0001) | 10/39 (< 0.0001) | 10/39 (< 0.0001) |
Interferon Signaling | 1/29 (0.1) | 1/29 (0.1) | 9/29 (< 0.0001) | 6/29 (< 0.005) | 6/29 (< 0.01) |
IL-10 Signaling | 1/70 (0.2) | 2/70 (< 0.05) | 12/70 (< 0.0001) | 12/70 (< 0.001) | 13/70 (< 0.0005) |
p38 MAPK Signaling | 1/95 (0.3) | 2/95 (0.1) | 13/95 (< 0.001) | 15/95 (< 0.0005) | 17/95 (< 0.0001) |
Cell Cycle: G2/M DNA Damage Checkpoint Regulation | N/A | N/A | 7/42 (< 0.01) | 5/42 (0.06) | 7/42 (< 0.01) |
Inositol Metabolism | N/A | N/A | 4/24 (< 0.005) | 3/24 (0.13) | 4/24 (< 0.05) |
Keratan Sulfate Biosynthesis | N/A | N/A | 5/31 (< 0.05) | 3/31 (026) | 5/31 (< 0.05) |
IL-6 Signaling | N/A | 1/93 (0.41) | 13/93 (< 0.0005) | 13/93 (< 0.005) | 15/93 (< 0.0005) |
Fatty Acid Metabolism | 1/187 (0.5) | 4/187 (< 0.05) | 28/187 (< 0.0001) | 26/187 (< 0.0001) | 28/187 (< 0.0001) |
Ranked according to P-value (as determined by IPA) | |||||
Total number of significant pathways | 2 | 6 | 15 | 44 | 40 |
Fatty Acid Metabolism | 1/187 (0.3) | 2/187 (0.1) | 28/187 (< 0.0001) | 25/187 (< 0.0001) | 28/187 (< 0.0001) |
LPS/IL-1 Mediated Inhibition of RXR Function | 1/170 (0.4) | 2/170 (0.2) | 33/170 (< 0.0001) | 26/170 (< 0.0001) | 31/170 (< 0.0001) |
Tryptophan Metabolism | 2/237 (0.05) | 1/237 (0.4) | 26/237 (< 0.0001) | 22/237 (< 0.0001) | 24/237 (< 0.0001) |
β-alanine Metabolism | N/A | N/A | 10/99 (< 0.0001) | 15/99 (< 0.0001) | 14/99 (< 0.0001) |
Valine, Leucine and Isoleucine Degradation | N/A | N/A | 12/107 (< 0.0001) | 14/107 (< 0.0005) | 16/107 (< 0.0001) |